Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The American Journal of Cardiology|March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical Cardiology|March 23, 2017
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9Amos Baruch, Diana Luca, Robert S Kahn, et al.
Bioanalysis|August 5, 2024
The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assaysKyra J Cowan, Lysie Champion, Daniel Dyer, et al.
Bioanalysis|April 9, 2025
Recent discussions and proposals on challenging the 3-tier immunogenicity testing strategies from the European bioanalysis forumKyra J Cowan, Karien Bloem, Annelies Coddens, et al.
Molecular Metabolism|September 20, 2013
Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaquesShijie Li, Paul Kievit, Anna-Karin Robertson, et al.
Bioanalysis|September 8, 2025
European Bioanalysis Forum recommendation on embracing a context-of-use-driven scientific validation for chromatographic assays in the light of ICH M10Philip Timmerman, Stuart McDougall, Neil Adcock, et al.
ALTEX|November 28, 2025
The Merck 3 Baskets approach for creating roadmaps to phase out animal testingKerstin Kleinschmidt-Doerr, Frederic C Pipp, Isabelle Colmagne-Poulard, et al.
Bioanalysis|March 19, 2026
From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis ForumKyra J Cowan, Rob Nelson, Annelies Coddens, et al.
Bioanalysis|July 29, 2022
Biomarker context-of-use: how organizational design can impact the implementation of the appropriate biomarker assay strategyKyra J Cowan, Michaela Golob, Joanne Goodman, et al.
Bioanalysis|August 9, 2024
Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis ForumJoanne Goodman, Kyra J Cowan, Michaela Golob, et al.
Pageof 4